WO2004070022A2 - Use of oxalate deficient aspergillus niger strains for producing a polypeptide - Google Patents

Use of oxalate deficient aspergillus niger strains for producing a polypeptide Download PDF

Info

Publication number
WO2004070022A2
WO2004070022A2 PCT/EP2004/001173 EP2004001173W WO2004070022A2 WO 2004070022 A2 WO2004070022 A2 WO 2004070022A2 EP 2004001173 W EP2004001173 W EP 2004001173W WO 2004070022 A2 WO2004070022 A2 WO 2004070022A2
Authority
WO
WIPO (PCT)
Prior art keywords
strain
oxalate
niger
wild type
enzyme
Prior art date
Application number
PCT/EP2004/001173
Other languages
French (fr)
Other versions
WO2004070022A3 (en
Inventor
Thibaut José WENZEL
Rogier Meulenberg
Jean-Marc Maurice Claude LADRIÈRE
Original Assignee
Dsm Ip Assets B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets B.V. filed Critical Dsm Ip Assets B.V.
Priority to US10/544,207 priority Critical patent/US20060127976A1/en
Priority to AU2004209618A priority patent/AU2004209618B2/en
Priority to JP2006501780A priority patent/JP2006516399A/en
Priority to CA002513833A priority patent/CA2513833A1/en
Priority to EP04708360A priority patent/EP1590444A2/en
Publication of WO2004070022A2 publication Critical patent/WO2004070022A2/en
Publication of WO2004070022A3 publication Critical patent/WO2004070022A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor
    • C12N1/145Fungal isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/645Fungi ; Processes using fungi
    • C12R2001/66Aspergillus
    • C12R2001/685Aspergillus niger

Definitions

  • the invention relates to oxalate deficient Aspergillus niger strains for producing a polypeptide, to their use and to a method for obtaining such strains.
  • Oxalic acid is an undesirable by-product that accumulates in the culture supernatant of cells during fermentation and causes difficulties in the downstream processing of the desirable compound.
  • -Ru2 RU2089615
  • New strains of A. niger has properties of producer of citric acid and can be used in microbiological industry (DW1998-249164).
  • -Ru3 The variability of A. niger, a producer of citric acid, under the influence of the separate and combined action of nitrosomethylurea and ultraviolet rays, E.Y.
  • WO 00/50576 describes that oxaloacetate hydrolase deficient host cells can be used for producing desirable compounds, such as polypeptides, primary and secondary metabolites. These host cells have less oxaloacetate hydrolase activity than the parental cells they originate from.
  • these oxaloacetate hydrolase (OAH) deficient cells produce less oxalic acid than the parental cells they originate from.
  • This patent application does not show experimental data demonstrating that an oxaloacetate hydrolase deficient cell is a suitable polypeptide producer.
  • Oxalate deficient A. niger strains suitable for the production of a given polypeptide or enzyme in an industrial setting have been isolated, wherein surprisingly the oxalate deficient strain produce at least the same amount of polypeptide or enzyme as the wild type strain they originate from under the same culture conditions. Preferably, the mutants produce at least the amount of polypeptide or enzyme the A. niger strain CBS 513.88 produces under the same culture condition.
  • A. niger strain CBS 513.88 is taken as a reference of wild type oxalate levels obtainable in an A. niger culture, as a reference of wild type polypeptide level obtainable in an A. niger culture and as a reference of intracellular OAH activity obtainable in an A. niger culture.
  • Oxalate deficient A. niger strains are defined as strains that produce less oxalate than the A. niger strain CBS 513.88 under the same culture conditions.
  • the oxalate deficient A. niger strains used produce no more than half the amount of oxalate that the wild type strain they originate from produces under the same culture conditions. More preferably, the oxalate deficient A.
  • the oxalate deficientA niger strains used produce no more than one fifth of the amount of oxalate that the wild type strain they originate from produces under the same culture conditions. More preferably, the oxalate deficient A. niger strains used produce no more than half the amount of oxalate that the A. niger strain CBS 513.88 produces under the same culture conditions. More preferably, the oxalate deficient A. n/gerstrains used produce no more than one third of the amount of oxalate that the A.
  • the oxalate deficient A. niger strains used produce no more than one fifth of the amount of oxalate that theA niger strain CBS 513.88 produces under the same culture conditions.
  • the oxalate deficient A. niger strain used has been obtained by applying the method defined later in this application.
  • the oxalate deficient A niger strains of the invention are strains that produce more of a given polypeptide than the wld type strain they originate from under the same culture conditions. More preferably, the oxalate deficientA niger strain produces more of a given polypeptide than the A niger CBS 513.88 under the same culture conditions.
  • Detection systems include any possible assay for detection of polypeptide or enzymatic activity.
  • these assay systems include but are not limited to assays based on colorimetric, photometric, turbidimetric, viscosimetric, immunological, biological, chromatographic, and other available assays.
  • the amount of active enzyme produced is determined by measurement of its activity in a model reaction (see examples).
  • the oxalate deficient A. niger strains of the invention are strains having a detectable intracellular OAH activity as detected in a model reaction (see experimental information in the Examples) More preferably, the oxalate deficientA n/gerstrains of the invention are strains having an intracellular OAH activity, which is ranged between 0.1 and 100 % of the intracellular OAH activity of the wild type strain they originate from as detected in a model reaction, preferably between 0.5 and 90, more preferably between 0.5 and 80, even more preferably between 1 and 50, most preferably between 1 and 25 and even most preferably between 1 and 10.
  • the oxalate deficient A niger strains have an intracellular OAH activity, which is ranged between 0.1 and 100% of the intracellular OAH activity of the CBS 513.88 deposited strain as detected in a model reaction. More preferably, the oxalate deficient A n/ger strains of the invention are strains having an intracellular OAH activity, which is ranged between 1 and 90% of the intracellular OAH activity of the CBS 513.88 deposited strain as detected in a model reaction.
  • the oxalate deficientA niger strain of the invention is characterized by the fact that when this strain has been transformed with an expression construct comprising a gene coding for a polypeptide, said strain produces at least the amount of the polypeptide the wild type strain it originates from would produce under the same culture conditions, when the wild type strain has also been transformed with the same expression construct as the oxalate deficient strain.
  • the gene coding for the polypeptide to be produced may be homologous or heterologous to the oxalate deficient A niger strain used.
  • heterologous means that the polypeptide is not native to the A niger cell.
  • the gene comprised in the expression construct is a heterologous gene for A niger.
  • Preferred heterologous polypeptide is human serum albumine, lactoferrin, chymosin or Phospho ⁇ pase A2.
  • the oxalate deficient strain has been transformed with a DNA construct comprising a DNA sequence encoding said polypeptide.
  • the polypeptide is an enzyme. Enzymes that can be produced are carbohydrases, e.g.
  • cellulases such as endoglucanases, ⁇ -glucanases, cellobiohydrolases or ⁇ -glucosideases, hemicellulases or pectinolytic enzymes such as xylanases, xylosidases, mannanases, galactanases, galactosidase, rhamnogalacturonases, arabanases, galacturonases, lyases, or amylolytic enzymes; phosphatases such as phytases, esterases such as lipases, proteolytic enzymes, oxidoreductases such as oxidases, transferases, or isomerases.
  • the amylolytic enzyme to be produced is an alpha amylase (EC 3.2.1.1., alpha-1 ,4-glucan-4- glucano hydrolase or EC 3.2.1.2) . More, preferably, the DNA sequence encodes a fungal alpha amylase. Most preferably, the DNA sequence encoding the fungal alpha amylase is derived from A niger or Aspergillus oryzae. According to another embodiment, the enzyme to be produced is a proline specific endoprotease (EC 3.4.16.2). According to another embodiment, the enzyme to be produced is a phospholipase A1 (PLA1) (EC 3.1.1.32). More, preferably, the DNA sequence encodes a fungal PLA1. Most preferably, the DNA sequence encoding the fungal PLA1 is derived from Aspergillus niger or Aspergillus oryzae.
  • PDA1 phospholipase A1
  • the DNA sequence encoding the fungal PLA1 is derived from Asper
  • the DNA sequence encoding the polypeptide to be produced may be operably linked to appropriate DNA regulatory regions to ensure a high level of expression of said DNA sequence and preferably a high secretion level of said polypeptide.
  • the polypeptide to be produced is native to Aspergillus niger, its native secretion signal is preferably used.
  • a fusion construct is preferably made comprising the glucoamylase gene of Aspergillus niger fused to the heterologous gene to be produced.
  • the regulatory regions of the Aspergillus oryzae alpha amylase gene are used.
  • the regulatory regions of the A niger glucoamylase gene are used.
  • the alpha amylase secretion signals are used.
  • the DNA construct may also comprise a selectable marker.
  • the selectable marker may be present on a second DNA construct.
  • these markers include but are not limited to amdS (acetamidase genes), auxotrophic marker genes such as argB, trpC, or pyrG and antibiotic resistance genes providing resistance against e.g. phleomycin, hygromycin B or G418.
  • the marker gene is the acetamidase gene from Aspergillus nidulans.
  • the acetamidase gene from Aspergillus nidulans is fused to the gpdA promoter. Transformation methods of A niger are well-known to the skilled person (Biotechnology of Filamentous fungi: Technology and Products. (1992) Reed Publishing (USA); Chapter 6: Transformation pages 113 to 156). The skilled person will recognize that successful transformation of A niger is not limited to the use of vectors, selection marker systems, promoters and transformation protocols specifically exemplified herein. After transformation, typically, the A niger population is cultivated on a solid medium in a petri dish. The transformants selected after culture on solid medium are typically cultivated in flask during three to seven days to check for expression of the polypeptide.
  • a fed-batch fermentation process may be used for producing the polypeptide in the oxalate deficientA niger strain in an industrial setting.
  • the polypeptide can be purified following techniques known to the skilled person. An example of such a recovery technique is explained in the following.
  • the host When the fermentation is stopped, the host must be killed. This is accomplished by adding a killing-off agent at some specific temperature where this agent can work effectively.
  • the killing-off agent may be natriumbenzoate or kaliumsorbate.
  • the broth temperature is adjusted to the corresponding working temperature of this agent, by using classical cooling methods known to the skilled person.
  • the separation of the cell material from the polypeptide is for example a simple filtration process: the fermentation broth is filtrated using a membrane filter press equipped with a textile cloth (membrane filter press and textile cloth can be obtained from Harborlite).
  • a suitable filter-aid can be used, together with a suitable pre-coat of the filter cloth.
  • the filtrate can be polished filtered on filter plates with an average pore size of typically 1-10 micron.
  • filter plates with an average pore size of typically 1-10 micron.
  • Several types of filter plates are known to the skilled person and are here suitable.
  • a germ filtration may be carried out using a filter with a pore size of about 0.4 micrometer, to remove the major part of microorganisms.
  • a pre-coat may be used to improve the filtration performance.
  • the filtrate may be then concentrated by ultrafiltration (UF) with a factor of typically 10-25.
  • UF membranes are suitable here.
  • UF molecules with a typical molecular weight of less than a few thousands (depending also on the shape of the molecules) are removed from the filtrate.
  • the relative amount of low molecular weight molecules to the polypeptide of interest may be reduced about 10-25 times after UF.
  • the duration of the UF varies depending on the viscosity and filterability of the filtrate (which varies due to natural variations in the raw materials).
  • the concentration of the polypeptide present in the ultrafiltrate is usually high enough to proceed with the formulation of the polypeptide into either a liquid or a dry formulation depending on the application contemplated.
  • a method for obtaining oxalate deficientA n/ger strains which are suitable for producing high yields of a polypeptide and which can be used as polypeptide producers in an industrial setting.
  • the polypeptide may be homologous or heterologous for said A niger.
  • the wild type strain on which the method of the invention is applied may have been earlier transformed to express a gene coding for such polypeptide or enzyme as has been described earlier in the description.
  • Such oxalate deficient A niger strains produce at least the amount of polypeptide the wild type strains they originate from produce under the same culture conditions.
  • the oxalate deficient A niger strains produce more polypeptide than the wild type strain they originate from under the same culture conditions.
  • the mutants produce at least the amount of polypeptide the A niger strain CBS 513.88 produced under the same culture condition. More preferably, the mutants produce more polypeptide than the A niger strain CBS 513.88 produced under the same culture conditions.
  • This method comprises the following steps: a) A. niger is subjected to UV irradiation, b) MTP cultures of surviving colonies obtained in a) are realized c) a selection within the MTP cultures is performed in which mutants are selected that produce no more than half the amount of oxalate that the wild type strain they originate from produces under the same culture conditions, d) a second selection is performed within the mutants obtained in step c) in which mutants are selected that produce at least the amount of polypeptide the wild type strains they originate from produce under the same culture conditions.
  • the method comprises the following steps: a) culture conditions are developed, which allow a production of at least 15 mM oxalate in microtiterplates (MTP) or at least 30 mM oxalate in flask culture in the fermentation medium at the end of fermentation, b) A niger is subjected to UV irradiation, c) MTP cultures of surviving colonies obtained in b) are realized under the culture conditions retained in a), d) a selection within the MTP cultures is performed in which mutants are selected that produce no more than half the amount of oxalate that the wild type strain they originate from produces under the same culture conditions, e) a second selection is performed within the mutants obtained in step d) in which mutants are selected that produce at least the amount of polypeptide the wild type strains they originate from produce under the same culture conditions.
  • MTP microtiterplates
  • the method comprises the following steps: a) culture conditions are developed, which allow a production of at least 15 mM oxalate in microtiterplates (MTP) or at least 30 mM oxalate in flask culture in the fermentation medium at the end of fermentation, b) A niger conidiospores are subjected to UV irradiation, c) MTP cultures of surviving colonies obtained in b) are realized under the culture conditions retained in a), d) a selection within the MTP cultures is performed in which mutants are selected that produce no more than half the amount of oxalate that the wild type strain they originate from produces under the same culture conditions, e) a second selection is performed within the mutants obtained in step d) in which mutants are selected that produce at least the amount of polypeptide the wild type strains they originate from produce under the same culture conditions.
  • MTP microtiterplates
  • the method comprises the following steps:
  • a niger is subjected to UV irradiation, b) MTP cultures of surviving colonies obtained in a),are realized, c) a selection within the MTP cultures is performed in which mutants are selected that produce at least the amount of polypeptide the wild type strains they originate from produce under the same culture conditions. d) a second selection is performed within the mutants obtained in c) in which mutants are selected that produce no more than half the amount of oxalate that the wild type strain they originate from produces under the same culture conditions,
  • colonies ofA niger are first cultivated in a medium which allows a production of at least 30 mM oxalate in MTP or at least 100 mM oxalate in flask culture in the fermentation medium at the end of fermentation.
  • the fermentation time should be at least 3 days.
  • the pH of this medium does not need to be manually corrected.
  • the pH of the medium of this step is maintained between 3 and 7, preferably between 3,5 and 6,5, more preferably between 4 and 6. Most preferably the pH of this medium is maintained between pH 5 and 6. At such a pH value, the production of oxalate is known to be high.
  • the pH of the medium is preferably buffered with a solution of 2-[N- Morpholinojethanesulfonic acid (MES) whose concentration is ranged between 0,1 and 1 M, more preferably between 0,15 and 0,55 M. Most preferably the MES concentration is 0,5 M.
  • MES 2-[N- Morpholinojethanesulfonic acid
  • the nitrogen source is a nitrogen source, which does not result in the acidification of the fermentation medium as a result of its uptake by the cell. More preferably, the nitrogen source of the medium of this step is urea.
  • the medium used in this step is the flask defined medium 2 (FDM2) (see example 1 ).
  • the A. niger strain used in this step is WT2 or the A niger strain CBS 513.88 (see experimental information).
  • a niger is subjected to UV irradiation so that the survival percentage is ranged between 0,01% and 60%.
  • the survival percentage is ranged between 0,05% and 50%. More preferably, the survival percentage is 0,1%.
  • conidiospores is the preferred material to mutagenizeA niger by physical or chemical means. Mutants may however also be obtained from mycelium cells. The selection method described herein may be applied to select mutants obtained from either conidiospores or mycelium cells.
  • MTP cultures of the surviving population obtained in a second step is performed during at least 3 days.
  • mutants can be selected in a fourth step on basis of their oxalate production (oxalate selection step).
  • mutants are selected that produce no more than one third of the amount of oxalate that the wild type strain they originate from produces under the same culture conditions. More preferably, mutants are selected that produce no more than one fifth of the amount of oxalate that the wild type strain they originate from produces under the same culture conditions.
  • a second selection step which can be applied to the mutants before or after the oxalate selection step is the following: select mutants that produce at least the amount of polypeptide the wild type strains they originate from produce ur er the same culture conditions. Preferably, the mutants produce more of a given polypeptide than the wild type strains they originate from under the same culture conditions.
  • the mutants produce at least the amourt of a given polypeptide the A niger strain CBS 513.88 produced under the same culture condition. More preferably, the mutants produce more of a given polypeptide than the A niger strain CBS 513.88 under the same culture conditions.
  • the mutants obtained in the previous step and a wild type control are cultivated in liquid medium for at least three days in a suitable medium. Preferably, the cultivation is performed during at least five days.
  • the amount of the polypeptide produced may be determined using a system for detection of said polypeptide as defined earlier on in the application.
  • the polypeptide produced is an enzyme
  • the amount of active enzyme produced is determined by measurement of its activity in a model reaction (see examples).
  • An optional sixth step may be further applied to select for oxalate deficientA niger strains having an intracellular OAH activity which is detectable as detected in a model reaction.
  • the model reaction is the one described in experimental information in the Examples. More preferably, this step allows the selection of oxalate deficientA n/ger strains having an intracellular OAH activity, which is ranged between 0.1 and 100 % of the intracellular OAH activity of the wild type strain they originate from as detected in a model reaction, preferably between 0.5 and 90, more preferably between 0.5 and 80, even more preferably between 1 and 50, most preferably between 1 and 25 and even most preferably between 1 and 10.
  • the oxalate deficient A niger strains have an intracellular OAH activity, which is ranged between 0.1 and 100% of the intracellular OAH activity of the CBS 513.88 deposited strain as detected in a model reaction. More preferably, the oxalate deficientA niger strains of the invention are strains having an intracellular OAH activity, which is ranged between 1 and 90% of the intracellular OAH activity of the CBS 513.88 deposited strain as detected in a model reaction.
  • the invention also relates to the use of an oxalate deficient A. niger strain for producing a given polypeptide. Accordingly, the invention also relates to a method for producing a given polypeptide wherein an oxalate deficient A.
  • Such strain produces at least the same amount of said polypeptide as the wild type strain it originates from under the same culture conditions. Preferably, the strain produces more of said polypeptide than the wild type it originates from under the same culture conditions. According to another preferred embodiment, the strain produces at least the same amount of said polypeptide or enzyme as the CBS 513.88 A. niger strain under the same culture conditions. More preferably, the strain produces more of said polypeptide or enzyme than the CBS 513.88 A. niger strain under the same culture conditions.
  • Figure 1 depicts the oxalate assay standard curve. The measured optical density is given as a function of the oxalate concentration present in solution.
  • Figure 2 depicts the evolution of the pH of the culture supernatant of wild type A niger during fermentation in FDM1 medium with or without pH correction.
  • Figure 3 depicts the average oxalate production obtained during fermentation of the wild type A niger in the FDM1 medium with or without pH correction.
  • Figure 4 depicts the average oxalate production obtained during fermentation of the wild type A niger in the FDM1 medium as a function of the MES concentration, with ammonium or urea as nitrogen source, without pH correction.
  • Figure 5 depicts the average oxalate production obtained during fermentation of the wild type A niger in the FDM2 medium without pH correction.
  • Figure 6 depicts the pH evolution during fermentation of wild type and some selected oxalate deficient A niger in the MDM1 medium.
  • Figure 7 depicts the average alpha amylase produced after fermentation in the FDM2 medium by the wild type and the 34 mutants as a function of their oxalate production.
  • Figure 8 depicts the measured OAH activity in three oxalate deficient A niger mutants and in the wild type.
  • Figure 9 depicts the average oxalate production obtained during the fermentation of the wild type and oxalate deficient A niger in the FDM2 medium without pH correction.
  • Figure 10 depicts the residual glucose concentration present during fermentation of wild type and oxalate deficient A niger in the FDM 2 medium.
  • Figure 1 1 depicts the pH evolution of culture supematants of wild type and oxalate deficient A. niger fermented in the FDM2 medium.
  • Figure 12 depicts the evolution of the biomass produced during fermentation of the wild type and oxalate deficient A niger in the FDM2 medium.
  • Figure 13 depicts the production of a praline specific endoprotease in WT1 and in FINAL (mutant 22) comprising the same estimated copy numbers of the gene coding for the proline specific endoprotease.
  • Figure 14 depicts the production of phospholipase A1 in WT1 and in FINAL (mutant 22) in shake flask.
  • WT 1 A. niger strain is used as a control for the level of oxalate,. the level of a given polypeptide and the level of intracellular OAH activity. This strain is deposited at the CBS Institute under the deposit number CBS 513.88.
  • WT 2 WT 1 strain comprising several copies of an expression cassette comprising the A oryzae alpha-amylase gene integrated in the genome. This gene was already described elsewhere (Wirsel et al., (1989), Mol. Microbiol. 3:3-14). The original signal sequence coded by the A. oryzae alpha-amylase gene was replaced by the one of the glucoamylase gene from A niger. WT 2 was constructed and selected by techniques known to persons skilled in the art and described in EP 635 574 A1 and in WO 98/46772.
  • MOPS Morpholino propanesulfonic acid
  • the oxaloacetic solution was prepared by dissolving 0.053 g of oxaloacetic acid in 10 ml of the assay buffer. 50 ⁇ l of the suspension obtained after centrifugation was added to the preheated mix. OAH activity was determined according to the method described by Pedersen et al, 2000, Mol. Gen. Genet. 263:281-286. Briefly, oxaloacetate is used as substrate. The enzyme activity was determined from the rate of decrease of the absorbance (delta A/min) at 255 nm during 3 minutes with a time interval of 20 seconds and the absorption coefficient of oxaloacetate. The assay was carried out at 25°C.
  • the protein content in the samples was determined according the Coomassie Plus Protein assay with Bovine Serum Albumin as a standard according to the manufacturer's instructions (Pierce, product number 23236).
  • alpha amylase is given as an example of enzyme that can be produced by an oxalate deficient A niger strain at a level which is at least the same as the one produced by the parental strain the mutant originate from under the same culture conditions.
  • Example 1 Method to make Oxalate deficient Aspergillus niger mutants which are high polypeptide producers are given as an example of enzyme that can be produced by an oxalate deficient A niger strain at a level which is at least the same as the one produced by the parental strain the mutant originate from under the same culture conditions.
  • Oxalate deficient niger mutants were made starting from WT2.
  • Cultures were performed at 34°C, in 96-wells microtiter plates (MTPs) or 300 ml flasks with one baffle in a rotary shaker at a shaking speed of 220 rpm.
  • Flask precultures were inoculated with 17 000 spores per ml. 100 ml cultures were inoculated with 10 ml of preculture.
  • Flask preculture medium 1 (FPM1), pH 5.5
  • Flask defined medium 1 FDM1
  • pH 6 Flask defined medium 1 (FDM1), pH 6
  • Flask defined medium 2 (FDM2), pH 6: the FDM2 medium had the same composition as FDM1 except that 15 grams per liter urea are present instead of 15 grams per liter (NH 4 ) 2 SO 4 .
  • This medium contained 100 grams per liter MES instead of 30 grams.
  • Microtiter plate defined medium 1 (MDM1), pH 6
  • the wild-type strain employed throughout this section is WT 1.
  • the pH has been described as the most critical parameter for oxalate pioduction.
  • the pH of A niger cultures should be maintained at a value close to 6 (Kubicek, C. P., et al, Appl. Environ. Microbiol. (1988) 54 , 633-637; and Ruijter, G. J. G., et al,. Microbiology (1999) 145, 2569-2576).
  • Oxalate production sharply decreases for pH values below 4 (Ruijter, G. J. G., van de Vondervoort, P. J. I., and Visser, J. 1999. Microbiology 145, 2569-2576).
  • a pH close to 6 can hardly be maintained in A niger cultures, because of the production of several organic acids by the fungus.
  • triplicate flasks cultures were performed with a wild-type A niger strain, either with or without daily manual pH correction by addition of sterile sodium hydroxyde.
  • a pre-culture phase of 48 hours in FPM1 medium was performed before FDM1 medium inoculation.
  • 0.15 M MES (30 g IL) was present to buffer the medium acidification during A niger growth.
  • the buffer present in the medium was not sufficient to counterbalance the production of organic acids by A. niger
  • figure 3 shows that the oxalate yield was greatly affected by the pH of the culture. Cultures in which the pH was corrected yielded about 5 times mote oxalate than the cultures in which the pH was not corrected.
  • a niger was grown in conditions yielding a maximal oxalate production, so that oxalate deficient strains could be selected and easily distinguished from a strain producing wild-type levels of oxalate.
  • FDM1 1 M MES affected the growth of A niger and an intermediate concentration of 0.5 M MES was chosen.
  • the growth medium finally chosen for flask cultivation during the screening was the FDM1 were the MES concentration was 0.5 M and where the ammonium sulfate was replaced by urea. From now on, that medium will be referred to as FDM2.
  • FIG. 5 shows that in FDM2, the oxalate concentration reached wthout pH correction was equivalent to the oxalate concentration reached in FDM1 with pH correction (compare with figure 3). So, there was no need for pH correction anymore.
  • a niger conidiospores were collected from WT 2 colonies sporulating on potato dextrose agar (PDA) medium (Difco, POTATO DEXTROSE AGAR, cultivation medium, catalogus. nr. 213400, year 1996-1997). 10 ml of a suspension containing 4x10 s conidiospores per ml was subjected to UV irradiation at 254 nm (Sylvania, 15 Watts Black Light Blue tube, model FT15T8/BLB) until an energy of 0,1783 J/crrt was received. A survival of 0.1% of the initial number of colonies was obtained.
  • PDA potato dextrose agar
  • the mutagenized spores solution was plated on PDA medium and 10 000 survivors were picked using a Genomic Solutions Flexys colony picker and further grown into 96 wells microtiter plates (MTP). These MTPs, called “masterplates” were incubated at 34°C until a strong sporulation was apparent. The masterplates were replica plated using the Genomic Solutions Flexys colony picker into MTPs containing 40 ⁇ l of FPM1 and incubated for 48 hours at 34°C. 170 ⁇ l of MDM1 was then added and the MTPs were further incubated for 7 days at 34°C.
  • the supernatant of the 10 000 individual cultures was assayed for the presence of oxalate.
  • the oxalate concentration reached in cultures of the WT 1 and WT 2 strains was in the range of 40 mM.
  • the mutants for which the oxalate concentration in the growth medium was below 12 mM were selected for a further selection round. 255 mutants were retained. This second selection round was more stringent than the first one, so that it allowed to get rid of false positives.
  • the second mutant selection consisted of a quadruplicate MTP cultivation and assay for oxalate.
  • the conditions employed were the same as the ones described here above.
  • Table 5, second column below lists the oxalate concentration reached in the lowest producers amongst the mutants and in wild-type MTP cultures.
  • 1 U/ml is the quantity of alpha amylase needed to convert 1 g soluble starch per hour into a product.
  • the formation of this product is being measured by following the absorption at 620 nm after addition of iode at pH 5.5 and at 30° C.
  • the incubation time with iode is between 15 and 25 minutes.
  • Figure 6 shows that the selected mutant strains acidify less the MDM1 growth medium upon growth compared to the wild-type strains. 5. Second selection: alpha amylase production
  • the 34 mutants obtained in the former paragraph were subsequently selected as to their capacities to produce alpha amylase.
  • the 34 mutants and WT2 were grown the same way as in the former paragraph, and characterized as to their alpha-amylase production.
  • the alpha-amylase activity present in culture supernatants was determined using the alpha amylase assay kit from Megazyme (Megazyme, CERALPHA alpha amylase assay kit, catalogus. ref. K-CERA, year 2000-2001).
  • Table 5 third column lists the average alpha amylase production detected in WT2 and in the 34 mutants.
  • Figure 7 depicts the average production of alpha amylase as a function of the oxalate production of the 34 mutants and the wild type. It could be observed in table 5, third column and in figure 7 that all the 34 mutants produced significantly more alpha-amylase than the wild-type strain they originated from. All the oxalate mutants found at the former paragraph were retained as mutants able to produce at least the same amount of enzyme as the wild type they originate from under the same culture conditions. Mutants 15, 19 and 22 were selected for further selection.
  • the intracellular OAH activity was measured in the three mutants (15, 19, 22) selected at the former paragraph and as a control in WT1 and WT2. For some strains, measurements were made twice (A, B) as indicated in figure 8. The test developed to measure OAH activity is described in experimental data. Mutants 15 and 22 showed a detectable OAH activity (figure 8): approximatively 10 to 20 % of the WT 1 or WT2. Surprisingly mutant 19 showed a high OAH activity, which is similar to the one of WT2. Surprisingly, these three oxalate deficient mutants still have a relative high OAH activity. Furthermore, they also have good enzyme production capacities.
  • Example 2 Example 2
  • FPM1 and FDM2 media as defined in example 1.
  • Mutants 18, 22, 15, 23, 19, 33 were grown in the FDM2 medium, after 48 hours of preculture phase in FPM1 , and characterized as to their oxalate production, and several growth parameters (residual glucose, pH and biomass formed).
  • the results obtained with the FDM2 medium confirmed the low level of oxalate production of the mutants compared to the wild-type strains (figure 9).
  • the residual glucose present in the FDM2 medium during growth of wild type and mutant strains was assayed using the Glucose assay kit from Sigma Diagnostics (Sigma, GLUCOSE diagnostic kit, catalogus nr. 510-A, year 2000-2001 ). As can be seen in figure 10, the glucose was almost completely consumed in some mutant cultures after 7 days of growth, suggesting the low oxalate level found in the selected mutant did not reflect a low metabolic activity. Only mutant 23 seemed to have a reduced metabolic activity.
  • the biomass formation was followed by weighing the biomass dry weight formed in the cultures at various cultivation times. Flasks were sacrificed at each time interval considered and the total biomass dry weight content of the flask was determined.
  • mutants showed various growth profiles but tended to reach the same biomass level as the parental strain WT 2 after 7 days of cultivation.
  • Mutant 23 was the only one which shown a low level of biomass formation, but this level was still comparable to the one reached by the wild-type strain WT 1 from which WT 2 originated.
  • Mutant 23 was not retained as oxalate deficient mutant for further characterization.
  • the sporulation capacities of the mutants were visually evaluated. It was found that the sporulation level of the mutants was comparable to the one of the wild type strain they originate from. Only one mutant seemed to have lower sporulation capacities.
  • mutant 22 was used as oxalate deficientA niger strain for producing different enzymes.
  • This mutant was obtained from WT2 and earlier on from WT1.
  • all the copies of the alpha amylase gene were deleted according to the method described in EP 635 574 A, using the acetamidase gene as selection marker gene.
  • This mutant empty of any foreign enzyme encoding gene would be named FINAL in the following examples.
  • FINAL was transformed with expression construct comprising the gene coding for the corresponding enzyme to be expressed as described in the following examples.
  • the expression constructs introduced in FINAL were also introduced in WT1 as described in the following examples. Copy number was checked. Mutant 22 was tested and compared to WT1 for the production of a proline specific endoprotease and PLA1. Mutant 22 produced the same amount of all enzymes tested as the WT1 it originates from under the same culture conditions or even more.
  • the proteolytic activity of the proline specific endoprotease was spectrophotometrically measured in time at pH 5 and about 37°C using Z-Gly(cine)- Pro(line)-pNA as a substrate.
  • 1 U proline specific endoprotease is defined as the amount of enzyme which converts 1 micromol Z-Gly(cine)-Pro(line)-pNA per min at pH 5 and at 37°C.
  • Figure 13 shows that the proline specific endoprotease activity of the A niger transformants with different estimated copy number is comprised in a range from 42 to 135 U/l. Strains with one estimated copy number have an activity of 42- 46 U/l and correlates well with the activity of two and three copy strains. We concluded that FINAL produces at least the same amount of proline specific endoprotease as WT1 under the same culture conditions.
  • PLA1 phospholipase A1
  • PLA1 hydrolyses the sulphide bond at the A1 position, dissociating thio-octano ⁇ c acid.
  • Thio-octano ⁇ c acid reacts with 4,4 dithiopyridine (color reagent, 4-DTDP), forming 4- thiopyridone.
  • 4-Thiopyridone is in tautomeric equilibrium with 4-mercaptopyridine, which absorbs radiation having a wavelength of 334 nm. The extinction change at that wavelength is measured.
  • One unit is the amount of enzyme that liberates of 1 nmol thio-octano ⁇ c acid from 1 ,2-dithiodioctanoyl phosphatidylcholine per minute at 37°C and pH 4.0.
  • the substrate solution is prepared by dissolving 1 g diC8 crystals per 66 ml ethanol and add 264 ml acetate buffer.
  • the acetate buffer comprises 0.1 M Acetate buffer pH 3.85 containing 0.2% Triton-X100.
  • the colour reagent is a 11 mM 4,4-dithiodipyridine solution. It was prepared by weighting 5,0 mg 4,4-dithiodipyridine in a 2 ml eppendorf sample cup and dissolving in 1.00 ml ethanol. 1.00 ml of milli-Q water was added. The results are depicted in figure 14. It is shown that PLA1 activity in transformants of WT1 cultures decreased after 4-5 days. However, the PLA1 activity of transformants of FINAL accumulates during fermentation and no decrease in activity could be observed. We concluded that FINAL produces more PLA1 than the wild type counterpart it originates from under the same culture conditions.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The invention relates to oxalate deficient A. niger strains for the production of a given enzyme, wherein the oxalate deficient strain produces at least the same amount of enzyme as the wild type strain it originates from under the same culture conditions. Preferably, the oxalate deficient A. niger strain produces more enzyme than the wild type strain it originates from under the same culture conditions. More preferably, the oxalate deficient A. niger strain is such that when the strain has been transformed with an expression construct comprising a gene coding for an enzyme, said strain produces at least the amount of the enzyme the wild type strain it originates from would produce under the same culture conditions, when the wild type strain has also been transformed with the same expression construct as the oxalate deficient strain. The invention also relates to method for obtaining such oxalate deficient A. niger strain. The present invention further relates to method for producing an enzyme, wherein an oxalate deficient A. niger strain that produces at least the same amount of enzyme as the wild type strain it originates from under the same culture conditions is used.

Description

USE OF OXALATE DEFICIENT ASPERGILLUS NIGER STRAINS FOR PRODUCING
A POLYPEPTIDE
Field of the invention
The invention relates to oxalate deficient Aspergillus niger strains for producing a polypeptide, to their use and to a method for obtaining such strains.
Background of the invention
Oxalic acid is an undesirable by-product that accumulates in the culture supernatant of cells during fermentation and causes difficulties in the downstream processing of the desirable compound.
Four Russian prior art documents, named„Ru1-Ru4 (defined hereafter), describe how to obtain oxalate deficient Aspergillus niger (A. niger) strains using classical mutagenesis methods. Oxalate deficient A. niger strains are defined as strains that produce less oxalic acid than the parental strain they originate from. They demonstrate that the choice of the mutagen agent is not critical: UV, or chemicals, or a combination of both as mutagen agents would lead to the obtention of oxalate deficient A. niger strains.
They use a chromatography assay to select strains that produce less oxalic acid or more citric acid than the parental strain they originate from. They do not envisage to use these strains for producing polypeptides. -Ru1 : On methods of selecting A. niger mutants with altered capacity to synthesize organic acids, ID Kasatkina and E.G. Zheltova, Mikrobiologiya, vol 34, no 3, p51 1-518, May-June 1965.
-Ru2:RU2089615, New strains of A. niger has properties of producer of citric acid and can be used in microbiological industry (DW1998-249164). -Ru3:The variability of A. niger, a producer of citric acid, under the influence of the separate and combined action of nitrosomethylurea and ultraviolet rays, E.Y.
Shcherbakova, Z.S. Karadzhova and V.P. Ermakova, Mikrobiologiya, vol 43, no 3, p508-
513, May-June 1974.
-Ru4: Change in the ratio of citric acid and oxalic acids in A. niger under the influence of mutagenic factors, V.M. Golubtsova, E.Y. Shcherbakova, L.Y. Runkovskaya and V.P. Eramkova, Mikrobiologiya, vol 48, no 6, p1060-1065, November-December Another publication, WO 00/50576 describes that oxaloacetate hydrolase deficient host cells can be used for producing desirable compounds, such as polypeptides, primary and secondary metabolites. These host cells have less oxaloacetate hydrolase activity than the parental cells they originate from. As a result, these oxaloacetate hydrolase (OAH) deficient cells produce less oxalic acid than the parental cells they originate from. This patent application does not show experimental data demonstrating that an oxaloacetate hydrolase deficient cell is a suitable polypeptide producer. Furthermore, Pedersen et al, (Pedersen, H., et al, Metabolic Eng., (2000) 2, 34-41 ) later described that oxaloacetate hydrolase deficient Aspergillus niger strains transformed with a DNA construct comprising the DNA sequence encoding the glucoamylase enzyme are not able to produce the glucoamylase enzyme at the level the wild type strain they originate from does under the same culture conditions: the mutants produce 50% less glucoamylase than the wild type. Such a mutant is not suited as a polypeptide producer in an industrial setting.
There is still a need for oxalate deficient A. niger strains that are able to produce at least the amount of a polypeptide a wild type strain would produce and that can be used as polypeptide producer in an industrial setting.
Detailed description of the invention
Oxalate deficient A. niger strains suitable for the production of a given polypeptide or enzyme in an industrial setting have been isolated, wherein surprisingly the oxalate deficient strain produce at least the same amount of polypeptide or enzyme as the wild type strain they originate from under the same culture conditions. Preferably, the mutants produce at least the amount of polypeptide or enzyme the A. niger strain CBS 513.88 produces under the same culture condition.
In this application, A. niger strain CBS 513.88 is taken as a reference of wild type oxalate levels obtainable in an A. niger culture, as a reference of wild type polypeptide level obtainable in an A. niger culture and as a reference of intracellular OAH activity obtainable in an A. niger culture. Oxalate deficient A. niger strains are defined as strains that produce less oxalate than the A. niger strain CBS 513.88 under the same culture conditions. Preferably, the oxalate deficient A. niger strains used produce no more than half the amount of oxalate that the wild type strain they originate from produces under the same culture conditions. More preferably, the oxalate deficient A. niger strains used produce no more than one third of the amount of oxalate that the wild type strain they originate from produces under the same culture conditions. Most preferably, the oxalate deficientA niger strains used produce no more than one fifth of the amount of oxalate that the wild type strain they originate from produces under the same culture conditions. More preferably, the oxalate deficient A. niger strains used produce no more than half the amount of oxalate that the A. niger strain CBS 513.88 produces under the same culture conditions. More preferably, the oxalate deficient A. n/gerstrains used produce no more than one third of the amount of oxalate that the A. niger strain CBS 513.88 produces under the same culture conditions. Most preferably, the oxalate deficient A. niger strains used produce no more than one fifth of the amount of oxalate that theA niger strain CBS 513.88 produces under the same culture conditions. According to a preferred embodiment of the inventbn, the oxalate deficient A. niger strain used has been obtained by applying the method defined later in this application.
Preferably, the oxalate deficient A niger strains of the invention are strains that produce more of a given polypeptide than the wld type strain they originate from under the same culture conditions. More preferably, the oxalate deficientA niger strain produces more of a given polypeptide than the A niger CBS 513.88 under the same culture conditions.
A large variety of systems for detection of polypeptide are known to the skilled person. Detection systems include any possible assay for detection of polypeptide or enzymatic activity. By way of example these assay systems include but are not limited to assays based on colorimetric, photometric, turbidimetric, viscosimetric, immunological, biological, chromatographic, and other available assays.
Preferably, if the polypeptide produced is an enzyme, the amount of active enzyme produced is determined by measurement of its activity in a model reaction (see examples).
Preferably, the oxalate deficient A. niger strains of the invention are strains having a detectable intracellular OAH activity as detected in a model reaction (see experimental information in the Examples) More preferably, the oxalate deficientA n/gerstrains of the invention are strains having an intracellular OAH activity, which is ranged between 0.1 and 100 % of the intracellular OAH activity of the wild type strain they originate from as detected in a model reaction, preferably between 0.5 and 90, more preferably between 0.5 and 80, even more preferably between 1 and 50, most preferably between 1 and 25 and even most preferably between 1 and 10. According to another preferred embodiment, the oxalate deficient A niger strains have an intracellular OAH activity, which is ranged between 0.1 and 100% of the intracellular OAH activity of the CBS 513.88 deposited strain as detected in a model reaction. More preferably, the oxalate deficient A n/ger strains of the invention are strains having an intracellular OAH activity, which is ranged between 1 and 90% of the intracellular OAH activity of the CBS 513.88 deposited strain as detected in a model reaction.
The existence of such oxalate deficient strains still having a detectable OAH activity, is surprising, since it was thought that OAH was the only molecule responsible for the formation of oxalate. Mutants still having detectable level of OAH activity have several advantages compared to oxalate deficient strains with no detectable OAH activity (Pedersen H et al, Metabolic Eng. (2000) 2, 34-41): they are able to produce at least the amount of a given polypeptide the wild type strain would produce under the same culture conditions. Furthermore, the endogenous metabolic pathway of organic acids is most likely not pertubated. According to a further preferred embodiment, the oxalate deficientA niger strain of the invention is characterized by the fact that when this strain has been transformed with an expression construct comprising a gene coding for a polypeptide, said strain produces at least the amount of the polypeptide the wild type strain it originates from would produce under the same culture conditions, when the wild type strain has also been transformed with the same expression construct as the oxalate deficient strain.
The gene coding for the polypeptide to be produced may be homologous or heterologous to the oxalate deficient A niger strain used. The term "heterologous" means that the polypeptide is not native to the A niger cell. Preferably, the gene comprised in the expression construct is a heterologous gene for A niger.
Preferred heterologous polypeptide is human serum albumine, lactoferrin, chymosin or Phosphoϋpase A2. According to a preferred embodiment of the invention, the oxalate deficient strain has been transformed with a DNA construct comprising a DNA sequence encoding said polypeptide. Preferably, the polypeptide is an enzyme. Enzymes that can be produced are carbohydrases, e.g. cellulases such as endoglucanases, β-glucanases, cellobiohydrolases or β-glucosideases, hemicellulases or pectinolytic enzymes such as xylanases, xylosidases, mannanases, galactanases, galactosidase, rhamnogalacturonases, arabanases, galacturonases, lyases, or amylolytic enzymes; phosphatases such as phytases, esterases such as lipases, proteolytic enzymes, oxidoreductases such as oxidases, transferases, or isomerases. Preferably, the amylolytic enzyme to be produced is an alpha amylase (EC 3.2.1.1., alpha-1 ,4-glucan-4- glucano hydrolase or EC 3.2.1.2) . More, preferably, the DNA sequence encodes a fungal alpha amylase. Most preferably, the DNA sequence encoding the fungal alpha amylase is derived from A niger or Aspergillus oryzae. According to another embodiment, the enzyme to be produced is a proline specific endoprotease (EC 3.4.16.2). According to another embodiment, the enzyme to be produced is a phospholipase A1 (PLA1) (EC 3.1.1.32). More, preferably, the DNA sequence encodes a fungal PLA1. Most preferably, the DNA sequence encoding the fungal PLA1 is derived from Aspergillus niger or Aspergillus oryzae.
The DNA sequence encoding the polypeptide to be produced may be operably linked to appropriate DNA regulatory regions to ensure a high level of expression of said DNA sequence and preferably a high secretion level of said polypeptide. If the polypeptide to be produced is native to Aspergillus niger, its native secretion signal is preferably used. Alternatively, if the polypeptide to be produced is not native toAspergillus niger, a fusion construct is preferably made comprising the glucoamylase gene of Aspergillus niger fused to the heterologous gene to be produced. According to a preferred embodiment of the invention, the regulatory regions of the Aspergillus oryzae alpha amylase gene are used. According to a more preferred embodiment of the invention, the regulatory regions of the A niger glucoamylase gene are used. According to a preferred embodiment of the invention, the alpha amylase secretion signals are used. The DNA construct may also comprise a selectable marker. Alternatively, the selectable marker may be present on a second DNA construct. By way of example these markers include but are not limited to amdS (acetamidase genes), auxotrophic marker genes such as argB, trpC, or pyrG and antibiotic resistance genes providing resistance against e.g. phleomycin, hygromycin B or G418. Preferably, the marker gene is the acetamidase gene from Aspergillus nidulans. More preferably, the acetamidase gene from Aspergillus nidulans is fused to the gpdA promoter. Transformation methods of A niger are well-known to the skilled person (Biotechnology of Filamentous fungi: Technology and Products. (1992) Reed Publishing (USA); Chapter 6: Transformation pages 113 to 156). The skilled person will recognize that successful transformation of A niger is not limited to the use of vectors, selection marker systems, promoters and transformation protocols specifically exemplified herein. After transformation, typically, the A niger population is cultivated on a solid medium in a petri dish. The transformants selected after culture on solid medium are typically cultivated in flask during three to seven days to check for expression of the polypeptide.
Typically, for producing the polypeptide in the oxalate deficientA niger strain in an industrial setting, a fed-batch fermentation process may be used. At the end of the fermentation, the polypeptide can be purified following techniques known to the skilled person. An example of such a recovery technique is explained in the following. When the fermentation is stopped, the host must be killed. This is accomplished by adding a killing-off agent at some specific temperature where this agent can work effectively. For example, the killing-off agent may be natriumbenzoate or kaliumsorbate. Depending on the identity of the killing-off agent chosen, the broth temperature is adjusted to the corresponding working temperature of this agent, by using classical cooling methods known to the skilled person. In the case of a polypeptide which is secreted into the fermentation medium, the separation of the cell material from the polypeptide is for example a simple filtration process: the fermentation broth is filtrated using a membrane filter press equipped with a textile cloth (membrane filter press and textile cloth can be obtained from Harborlite). To improve the filtration performance, a suitable filter-aid can be used, together with a suitable pre-coat of the filter cloth.
To remove any remaining small particles, additional filtration steps can be carried out, in such a way that a clear filtrate can be obtained. The filtrate can be polished filtered on filter plates with an average pore size of typically 1-10 micron. Several types of filter plates are known to the skilled person and are here suitable. Subsequently, a germ filtration may be carried out using a filter with a pore size of about 0.4 micrometer, to remove the major part of microorganisms. With these two filtrations, a pre-coat may be used to improve the filtration performance. The filtrate may be then concentrated by ultrafiltration (UF) with a factor of typically 10-25. Several types of UF membranes are suitable here. During UF molecules with a typical molecular weight of less than a few thousands (depending also on the shape of the molecules) are removed from the filtrate. Thus, the relative amount of low molecular weight molecules to the polypeptide of interest may be reduced about 10-25 times after UF. The duration of the UF varies depending on the viscosity and filterability of the filtrate (which varies due to natural variations in the raw materials). At that stage, the concentration of the polypeptide present in the ultrafiltrate is usually high enough to proceed with the formulation of the polypeptide into either a liquid or a dry formulation depending on the application contemplated.
A method was developed for obtaining oxalate deficientA n/ger strains which are suitable for producing high yields of a polypeptide and which can be used as polypeptide producers in an industrial setting. The polypeptide may be homologous or heterologous for said A niger. In case of a heterologous polypeptide or enzyme, the wild type strain on which the method of the invention is applied may have been earlier transformed to express a gene coding for such polypeptide or enzyme as has been described earlier in the description. Such oxalate deficient A niger strains produce at least the amount of polypeptide the wild type strains they originate from produce under the same culture conditions. Preferably, the oxalate deficient A niger strains produce more polypeptide than the wild type strain they originate from under the same culture conditions. According to another preferred embodiment, the mutants produce at least the amount of polypeptide the A niger strain CBS 513.88 produced under the same culture condition. More preferably, the mutants produce more polypeptide than the A niger strain CBS 513.88 produced under the same culture conditions.
This method comprises the following steps: a) A. niger is subjected to UV irradiation, b) MTP cultures of surviving colonies obtained in a) are realized c) a selection within the MTP cultures is performed in which mutants are selected that produce no more than half the amount of oxalate that the wild type strain they originate from produces under the same culture conditions, d) a second selection is performed within the mutants obtained in step c) in which mutants are selected that produce at least the amount of polypeptide the wild type strains they originate from produce under the same culture conditions.
According to a preferred embodiment, the method comprises the following steps: a) culture conditions are developed, which allow a production of at least 15 mM oxalate in microtiterplates (MTP) or at least 30 mM oxalate in flask culture in the fermentation medium at the end of fermentation, b) A niger is subjected to UV irradiation, c) MTP cultures of surviving colonies obtained in b) are realized under the culture conditions retained in a), d) a selection within the MTP cultures is performed in which mutants are selected that produce no more than half the amount of oxalate that the wild type strain they originate from produces under the same culture conditions, e) a second selection is performed within the mutants obtained in step d) in which mutants are selected that produce at least the amount of polypeptide the wild type strains they originate from produce under the same culture conditions.
According to another preferred embodiment, the method comprises the following steps: a) culture conditions are developed, which allow a production of at least 15 mM oxalate in microtiterplates (MTP) or at least 30 mM oxalate in flask culture in the fermentation medium at the end of fermentation, b) A niger conidiospores are subjected to UV irradiation, c) MTP cultures of surviving colonies obtained in b) are realized under the culture conditions retained in a), d) a selection within the MTP cultures is performed in which mutants are selected that produce no more than half the amount of oxalate that the wild type strain they originate from produces under the same culture conditions, e) a second selection is performed within the mutants obtained in step d) in which mutants are selected that produce at least the amount of polypeptide the wild type strains they originate from produce under the same culture conditions.
According to another preferred embodiment, the method comprises the following steps:
a) A niger is subjected to UV irradiation, b) MTP cultures of surviving colonies obtained in a),are realized, c) a selection within the MTP cultures is performed in which mutants are selected that produce at least the amount of polypeptide the wild type strains they originate from produce under the same culture conditions. d) a second selection is performed within the mutants obtained in c) in which mutants are selected that produce no more than half the amount of oxalate that the wild type strain they originate from produces under the same culture conditions,
Each step of these processes is characterized further below.
According to a preferred embodiment of the invention, in a first step, colonies ofA niger are first cultivated in a medium which allows a production of at least 30 mM oxalate in MTP or at least 100 mM oxalate in flask culture in the fermentation medium at the end of fermentation. The fermentation time should be at least 3 days. It is further a preferred embodiment of the method that the pH of this medium does not need to be manually corrected. The pH of the medium of this step is maintained between 3 and 7, preferably between 3,5 and 6,5, more preferably between 4 and 6. Most preferably the pH of this medium is maintained between pH 5 and 6. At such a pH value, the production of oxalate is known to be high. The pH of the medium is preferably buffered with a solution of 2-[N- Morpholinojethanesulfonic acid (MES) whose concentration is ranged between 0,1 and 1 M, more preferably between 0,15 and 0,55 M. Most preferably the MES concentration is 0,5 M. A nitrogen source is present in the medium of this step. Preferably the nitrogen source is a nitrogen source, which does not result in the acidification of the fermentation medium as a result of its uptake by the cell. More preferably, the nitrogen source of the medium of this step is urea. According to a preferred embodiment of the present invention, the medium used in this step is the flask defined medium 2 (FDM2) (see example 1 ). According to a preferred embodiment of the present invention, the A. niger strain used in this step is WT2 or the A niger strain CBS 513.88 (see experimental information).
In a second step, A niger is subjected to UV irradiation so that the survival percentage is ranged between 0,01% and 60%. Preferably, the survival percentage is ranged between 0,05% and 50%. More preferably, the survival percentage is 0,1%. It is well known to the skilled person that conidiospores is the preferred material to mutagenizeA niger by physical or chemical means. Mutants may however also be obtained from mycelium cells. The selection method described herein may be applied to select mutants obtained from either conidiospores or mycelium cells.
In a third step, MTP cultures of the surviving population obtained in a second step is performed during at least 3 days.
At the end of the MTP culture of the third step, mutants can be selected in a fourth step on basis of their oxalate production (oxalate selection step). Preferably mutants are selected that produce no more than one third of the amount of oxalate that the wild type strain they originate from produces under the same culture conditions. More preferably, mutants are selected that produce no more than one fifth of the amount of oxalate that the wild type strain they originate from produces under the same culture conditions.
An assay to quantify the oxalate present in the medium that may be used is described in the Examples. For practical reasons, the best mutants (the lowest oxalate producers) are retained for further characterization. Preferably 5 to 50 mutants are retained for further characterization. Typically, after 7 days in flask cultivation, it can be checked that these selected mutants produce far less oxalate than the wild type strain: in the case described in figure 7, less than 5 mM oxalate is found in the fermentation medium of the mutants compared to 40-45 mM for the wild type strain. After 7 days of fermentation, it can further be checked whether the medium is less acidified by the selected mutants than by the wild type strain. It can also be checked by measurement of the biomass produced and by measurement of the residual glucose concentration at different intervals during fermentation that the low level of oxalate measured in the mutants is not the consequence of either a poor growth and/or a poor metabolic activity of the selected mutants. A second selection step which can be applied to the mutants before or after the oxalate selection step is the following: select mutants that produce at least the amount of polypeptide the wild type strains they originate from produce ur er the same culture conditions. Preferably, the mutants produce more of a given polypeptide than the wild type strains they originate from under the same culture conditions. According to another preferred embodiment, the mutants produce at least the amourt of a given polypeptide the A niger strain CBS 513.88 produced under the same culture condition. More preferably, the mutants produce more of a given polypeptide than the A niger strain CBS 513.88 under the same culture conditions. To perform this last step, the mutants obtained in the previous step and a wild type control are cultivated in liquid medium for at least three days in a suitable medium. Preferably, the cultivation is performed during at least five days. At the end of the culture, the amount of the polypeptide produced may be determined using a system for detection of said polypeptide as defined earlier on in the application. Preferably, if the polypeptide produced is an enzyme, the amount of active enzyme produced is determined by measurement of its activity in a model reaction (see examples).
An optional sixth step may be further applied to select for oxalate deficientA niger strains having an intracellular OAH activity which is detectable as detected in a model reaction. Preferably, the model reaction is the one described in experimental information in the Examples. More preferably, this step allows the selection of oxalate deficientA n/ger strains having an intracellular OAH activity, which is ranged between 0.1 and 100 % of the intracellular OAH activity of the wild type strain they originate from as detected in a model reaction, preferably between 0.5 and 90, more preferably between 0.5 and 80, even more preferably between 1 and 50, most preferably between 1 and 25 and even most preferably between 1 and 10. According to another preferred embodiment, the oxalate deficient A niger strains have an intracellular OAH activity, which is ranged between 0.1 and 100% of the intracellular OAH activity of the CBS 513.88 deposited strain as detected in a model reaction. More preferably, the oxalate deficientA niger strains of the invention are strains having an intracellular OAH activity, which is ranged between 1 and 90% of the intracellular OAH activity of the CBS 513.88 deposited strain as detected in a model reaction. The invention also relates to the use of an oxalate deficient A. niger strain for producing a given polypeptide. Accordingly, the invention also relates to a method for producing a given polypeptide wherein an oxalate deficient A. niger as defined in this application is used. Such strain produces at least the same amount of said polypeptide as the wild type strain it originates from under the same culture conditions. Preferably, the strain produces more of said polypeptide than the wild type it originates from under the same culture conditions. According to another preferred embodiment, the strain produces at least the same amount of said polypeptide or enzyme as the CBS 513.88 A. niger strain under the same culture conditions. More preferably, the strain produces more of said polypeptide or enzyme than the CBS 513.88 A. niger strain under the same culture conditions.
Brief description of the drawings:
Figure 1 depicts the oxalate assay standard curve. The measured optical density is given as a function of the oxalate concentration present in solution. Figure 2 depicts the evolution of the pH of the culture supernatant of wild type A niger during fermentation in FDM1 medium with or without pH correction.
Figure 3 depicts the average oxalate production obtained during fermentation of the wild type A niger in the FDM1 medium with or without pH correction.
Figure 4 depicts the average oxalate production obtained during fermentation of the wild type A niger in the FDM1 medium as a function of the MES concentration, with ammonium or urea as nitrogen source, without pH correction.
Figure 5 depicts the average oxalate production obtained during fermentation of the wild type A niger in the FDM2 medium without pH correction.
Figure 6 depicts the pH evolution during fermentation of wild type and some selected oxalate deficient A niger in the MDM1 medium.
Figure 7 depicts the average alpha amylase produced after fermentation in the FDM2 medium by the wild type and the 34 mutants as a function of their oxalate production.
Figure 8 depicts the measured OAH activity in three oxalate deficient A niger mutants and in the wild type.
Figure 9 depicts the average oxalate production obtained during the fermentation of the wild type and oxalate deficient A niger in the FDM2 medium without pH correction.
Figure 10 depicts the residual glucose concentration present during fermentation of wild type and oxalate deficient A niger in the FDM 2 medium. Figure 1 1 depicts the pH evolution of culture supematants of wild type and oxalate deficient A. niger fermented in the FDM2 medium.
Figure 12 depicts the evolution of the biomass produced during fermentation of the wild type and oxalate deficient A niger in the FDM2 medium.
Figure 13 depicts the production of a praline specific endoprotease in WT1 and in FINAL (mutant 22) comprising the same estimated copy numbers of the gene coding for the proline specific endoprotease.
Figure 14 depicts the production of phospholipase A1 in WT1 and in FINAL (mutant 22) in shake flask. EXAMPLES
Experimental information
Strains
WT 1 : A. niger strain is used as a control for the level of oxalate,. the level of a given polypeptide and the level of intracellular OAH activity. This strain is deposited at the CBS Institute under the deposit number CBS 513.88.
WT 2: WT 1 strain comprising several copies of an expression cassette comprising the A oryzae alpha-amylase gene integrated in the genome. This gene was already described elsewhere (Wirsel et al., (1989), Mol. Microbiol. 3:3-14).The original signal sequence coded by the A. oryzae alpha-amylase gene was replaced by the one of the glucoamylase gene from A niger. WT 2 was constructed and selected by techniques known to persons skilled in the art and described in EP 635 574 A1 and in WO 98/46772.
OAH activity assay
Shake flask fermentations of different A niger strains were performed as decribed hereafter. Cells were cultivated at 30°C, 170 rpm for three days in 100ml of OAH cultivation medium in 500 ml shake flasks without a baffle. The OAH medium is defined in Table 1 below.Then, the pH was shifted to 8 by addition of Na2CO3 and cells were cultivated for an additional 15 to 18 hours. Mycelium was harvested by filtration, washed with 0.9% (w/v) NaCI, frozen in liquid nitrogen and stored at -80°C. Frozen cells were disrupted in a mortar under liquid nitrogen and then suspended in the following extraction buffer: 100 mM MOPS buffer pH 7.5 (MOPS = Morpholino propanesulfonic acid), 2 mM MnCI2, 20 mM DTT, 5% sucrose. The suspension was centrifuged for 20 min. at 14,000 r.p.m. at 4°C in an Eppendorf centrifuge 5417R. 925 μl of the assay buffer (assay buffer: 100 mM MOPS pH 7.5 / 2 mM Mn 2+) was pre-heated at 25°C. 25 μl of a 40 mM oxaloacetic solution was added to this preheated mix. The oxaloacetic solution was prepared by dissolving 0.053 g of oxaloacetic acid in 10 ml of the assay buffer. 50 μl of the suspension obtained after centrifugation was added to the preheated mix. OAH activity was determined according to the method described by Pedersen et al, 2000, Mol. Gen. Genet. 263:281-286. Briefly, oxaloacetate is used as substrate. The enzyme activity was determined from the rate of decrease of the absorbance (delta A/min) at 255 nm during 3 minutes with a time interval of 20 seconds and the absorption coefficient of oxaloacetate. The assay was carried out at 25°C.
Table 1 :
OAH medium
Trace Metal Solution
ZnSO4-7H2O 0.143 g
CuS04-5H2O 0.025 g
NiCI2-6H2O 0.005 g
FeSO4-7H2O 0.138 g
MnCI2-4H2O 0.060 g
Water up to 10 ml
OAH medium, pH = 2.5 or 4.5,
Sucrose 20 g
KH2PO4 1.5 g
MgSO4-7H2O 1 9
NaCI 1 g
CaCI2-2H2O 0.1 g
NaNO3 15 g
Trace Metal solution 0.5 ml
(Adjust pH to 2.5 with HCI) Water up to 1 liter
Protein assay
The protein content in the samples was determined according the Coomassie Plus Protein assay with Bovine Serum Albumin as a standard according to the manufacturer's instructions (Pierce, product number 23236).
In Example 1 , alpha amylase is given as an example of enzyme that can be produced by an oxalate deficient A niger strain at a level which is at least the same as the one produced by the parental strain the mutant originate from under the same culture conditions. Example 1 Method to make Oxalate deficient Aspergillus niger mutants which are high polypeptide producers
Oxalate deficient niger mutants were made starting from WT2.
1. Growth media
Cultures were performed at 34°C, in 96-wells microtiter plates (MTPs) or 300 ml flasks with one baffle in a rotary shaker at a shaking speed of 220 rpm.
Flask precultures were inoculated with 17 000 spores per ml. 100 ml cultures were inoculated with 10 ml of preculture.
Table 2
Flask preculture medium 1 (FPM1), pH 5.5
(all components are given in grams per liter)
Figure imgf000017_0001
Table 3
Flask defined medium 1 (FDM1), pH 6
(all components are given in grams per liter)
Figure imgf000017_0002
Figure imgf000018_0001
Flask defined medium 2 (FDM2), pH 6: the FDM2 medium had the same composition as FDM1 except that 15 grams per liter urea are present instead of 15 grams per liter (NH4)2SO4. This medium contained 100 grams per liter MES instead of 30 grams.
Table 4
Microtiter plate defined medium 1 (MDM1), pH 6
(all components are given in grams per liter)
Figure imgf000018_0002
2. Assay for oxalate detection in A. niger culture supernatant
A commercial kit available from Sigma diagnostics (Sigma. OXALATE diagnostic kit, catalogus. nr. 591 year 2000-2001) was employed for oxalate quantification. The volumes recommended by the manufacturer were downscaled to reach a final assay volume of 48 μl, the assay being performed in 384-wells MTPs. A Beckman Multimek 96 was employed for all liquid transfers and the absorbance was read at 550 nm in a BMG spectrofluorimeter. The Oxalate assay standard curve is given in Figure 1 (the optical density, OD, as a function of the oxalate concentration). In these conditions, he assay was found to be linear up to 2.5 mM.
3. Development of cultivation conditions to maximize oxalate production
The wild-type strain employed throughout this section is WT 1.
The pH has been described as the most critical parameter for oxalate pioduction. To achieve a high oxalate production, the pH of A niger cultures should be maintained at a value close to 6 (Kubicek, C. P., et al, Appl. Environ. Microbiol. (1988) 54 , 633-637; and Ruijter, G. J. G., et al,. Microbiology (1999) 145, 2569-2576). Oxalate production sharply decreases for pH values below 4 (Ruijter, G. J. G., van de Vondervoort, P. J. I., and Visser, J. 1999. Microbiology 145, 2569-2576). A pH close to 6 can hardly be maintained in A niger cultures, because of the production of several organic acids by the fungus. To test how critical the pH of the culture was in the FDM1 medium, triplicate flasks cultures were performed with a wild-type A niger strain, either with or without daily manual pH correction by addition of sterile sodium hydroxyde. A pre-culture phase of 48 hours in FPM1 medium was performed before FDM1 medium inoculation. In FDM1 medium, 0.15 M MES (30 g IL) was present to buffer the medium acidification during A niger growth.
As can be seen in figure 2, the buffer present in the medium was not sufficient to counterbalance the production of organic acids by A. niger, and figure 3 shows that the oxalate yield was greatly affected by the pH of the culture. Cultures in which the pH was corrected yielded about 5 times mote oxalate than the cultures in which the pH was not corrected. During the screening for oxalate deficient strains, A niger was grown in conditions yielding a maximal oxalate production, so that oxalate deficient strains could be selected and easily distinguished from a strain producing wild-type levels of oxalate. For practical reasons, a manual pH correction could not be an option to achieve a maximal oxalate production in the initial screening phase, when a huge number of mutants were still under evaluation. To improve the level of oxalate production without having the need to correct the pH of the cultures, two parameters were tuned in the FDM1 medium, which were the MES concentration in the medium and the nature of the nitrogen source.
As shown in figure 4, increasing the MES concentration and replacing ammonium sulfate by urea had a major impact on the maximal oxalate concentration, which could be reached in A niger cultures without pH correction. In figure 5, the maximal oxalate concentration reached after 6 or 7 days of fermentation depending on the composition of the fermentation medium is represented.
1 M MES affected the growth of A niger and an intermediate concentration of 0.5 M MES was chosen. Thus the growth medium finally chosen for flask cultivation during the screening was the FDM1 were the MES concentration was 0.5 M and where the ammonium sulfate was replaced by urea. From now on, that medium will be referred to as FDM2.
Figure 5 shows that in FDM2, the oxalate concentration reached wthout pH correction was equivalent to the oxalate concentration reached in FDM1 with pH correction (compare with figure 3). So, there was no need for pH correction anymore.
4. First selection: oxalate production
A niger conidiospores were collected from WT 2 colonies sporulating on potato dextrose agar (PDA) medium (Difco, POTATO DEXTROSE AGAR, cultivation medium, catalogus. nr. 213400, year 1996-1997). 10 ml of a suspension containing 4x10s conidiospores per ml was subjected to UV irradiation at 254 nm (Sylvania, 15 Watts Black Light Blue tube, model FT15T8/BLB) until an energy of 0,1783 J/crrt was received. A survival of 0.1% of the initial number of colonies was obtained. The mutagenized spores solution was plated on PDA medium and 10 000 survivors were picked using a Genomic Solutions Flexys colony picker and further grown into 96 wells microtiter plates (MTP). These MTPs, called "masterplates" were incubated at 34°C until a strong sporulation was apparent. The masterplates were replica plated using the Genomic Solutions Flexys colony picker into MTPs containing 40 μl of FPM1 and incubated for 48 hours at 34°C. 170 μl of MDM1 was then added and the MTPs were further incubated for 7 days at 34°C.
The supernatant of the 10 000 individual cultures was assayed for the presence of oxalate. In the cultivation conditions employed, the oxalate concentration reached in cultures of the WT 1 and WT 2 strains was in the range of 40 mM. The mutants for which the oxalate concentration in the growth medium was below 12 mM were selected for a further selection round. 255 mutants were retained. This second selection round was more stringent than the first one, so that it allowed to get rid of false positives.
The second mutant selection consisted of a quadruplicate MTP cultivation and assay for oxalate. The conditions employed were the same as the ones described here above. Table 5, second column below lists the oxalate concentration reached in the lowest producers amongst the mutants and in wild-type MTP cultures.
Table 5 Mutants
Figure imgf000021_0001
Figure imgf000022_0001
1 U/ml is the quantity of alpha amylase needed to convert 1 g soluble starch per hour into a product. The formation of this product is being measured by following the absorption at 620 nm after addition of iode at pH 5.5 and at 30° C. The incubation time with iode is between 15 and 25 minutes.
Figure 6 shows that the selected mutant strains acidify less the MDM1 growth medium upon growth compared to the wild-type strains. 5. Second selection: alpha amylase production
As a second selection step, the 34 mutants obtained in the former paragraph were subsequently selected as to their capacities to produce alpha amylase.
The 34 mutants and WT2 were grown the same way as in the former paragraph, and characterized as to their alpha-amylase production.
The alpha-amylase activity present in culture supernatants was determined using the alpha amylase assay kit from Megazyme (Megazyme, CERALPHA alpha amylase assay kit, catalogus. ref. K-CERA, year 2000-2001). Table 5 third column lists the average alpha amylase production detected in WT2 and in the 34 mutants. Figure 7 depicts the average production of alpha amylase as a function of the oxalate production of the 34 mutants and the wild type. It could be observed in table 5, third column and in figure 7 that all the 34 mutants produced significantly more alpha-amylase than the wild-type strain they originated from. All the oxalate mutants found at the former paragraph were retained as mutants able to produce at least the same amount of enzyme as the wild type they originate from under the same culture conditions. Mutants 15, 19 and 22 were selected for further selection.
6. Third selection: OAH activity
As an additional selection, the intracellular OAH activity was measured in the three mutants (15, 19, 22) selected at the former paragraph and as a control in WT1 and WT2. For some strains, measurements were made twice (A, B) as indicated in figure 8. The test developed to measure OAH activity is described in experimental data. Mutants 15 and 22 showed a detectable OAH activity (figure 8): approximatively 10 to 20 % of the WT 1 or WT2. Surprisingly mutant 19 showed a high OAH activity, which is similar to the one of WT2. Surprisingly, these three oxalate deficient mutants still have a relative high OAH activity. Furthermore, they also have good enzyme production capacities. Example 2
Characterisation of the A. niger oxalate deficient mutants
1. Growth media
Table 6
FPM1 and FDM2 media; as defined in example 1. Flask preculture medium 2 (FPM2), pH 5.5
(all components are given in grams per liter)
Figure imgf000024_0001
2. Characterization of the A. niger oxalate deficient mutants
Mutants 18, 22, 15, 23, 19, 33 were grown in the FDM2 medium, after 48 hours of preculture phase in FPM1 , and characterized as to their oxalate production, and several growth parameters (residual glucose, pH and biomass formed). The results obtained with the FDM2 medium confirmed the low level of oxalate production of the mutants compared to the wild-type strains (figure 9).
The residual glucose present in the FDM2 medium during growth of wild type and mutant strains was assayed using the Glucose assay kit from Sigma Diagnostics (Sigma, GLUCOSE diagnostic kit, catalogus nr. 510-A, year 2000-2001 ). As can be seen in figure 10, the glucose was almost completely consumed in some mutant cultures after 7 days of growth, suggesting the low oxalate level found in the selected mutant did not reflect a low metabolic activity. Only mutant 23 seemed to have a reduced metabolic activity.
The pH of the cultures was also followed. As previously observed (see example 1 ), the acidification of the culture medium was less advanced in the mutants than in wild- type cultures (See figure 11 ).
Finally, to ensure that the reduced oxalate production of the mutants was not due to a poor growth, the biomass formation was followed by weighing the biomass dry weight formed in the cultures at various cultivation times. Flasks were sacrificed at each time interval considered and the total biomass dry weight content of the flask was determined.
As can be seen in figure 12, the mutants showed various growth profiles but tended to reach the same biomass level as the parental strain WT 2 after 7 days of cultivation. Mutant 23 was the only one which shown a low level of biomass formation, but this level was still comparable to the one reached by the wild-type strain WT 1 from which WT 2 originated. Mutant 23 was not retained as oxalate deficient mutant for further characterization. The sporulation capacities of the mutants were visually evaluated. It was found that the sporulation level of the mutants was comparable to the one of the wild type strain they originate from. Only one mutant seemed to have lower sporulation capacities. In the following examples, mutant 22 was used as oxalate deficientA niger strain for producing different enzymes. This mutant was obtained from WT2 and earlier on from WT1. In order to express other enzymes in this mutant, all the copies of the alpha amylase gene were deleted according to the method described in EP 635 574 A, using the acetamidase gene as selection marker gene. This mutant empty of any foreign enzyme encoding gene would be named FINAL in the following examples. Subsequently, FINAL was transformed with expression construct comprising the gene coding for the corresponding enzyme to be expressed as described in the following examples. In order to express specific enzymes in WT1 , the expression constructs introduced in FINAL were also introduced in WT1 as described in the following examples. Copy number was checked. Mutant 22 was tested and compared to WT1 for the production of a proline specific endoprotease and PLA1. Mutant 22 produced the same amount of all enzymes tested as the WT1 it originates from under the same culture conditions or even more. Example 3
Comparison of the production of a proline specific endoprotease in the WT1 and in FINAL strains
The gene coding for the proline specific endoprotease, which has been used has already been published elsewhere (WO 02/45524). In order to express the proline specific endoprotease described in WO 02/45524 in WT1 and in FINAL, the construct depicted in WO 02/45524 (pGBFIN11-EPO) was introduced in these strains by cotransformation as described in WO 02/45524. Transformants with similar estimated copy number were selected to perform shake flask experiments in 100 ml of the medium as described in EP 635 574 A1 at 34°C and 170 rpm in an incubator shaker using a 500 ml baffeled shake flask. After four days of fermentation, samples were taken to determine the proline specific endoprotease activity. The proteolytic activity of the proline specific endoprotease was spectrophotometrically measured in time at pH 5 and about 37°C using Z-Gly(cine)- Pro(line)-pNA as a substrate. 1 U proline specific endoprotease is defined as the amount of enzyme which converts 1 micromol Z-Gly(cine)-Pro(line)-pNA per min at pH 5 and at 37°C.
Figure 13 shows that the proline specific endoprotease activity of the A niger transformants with different estimated copy number is comprised in a range from 42 to 135 U/l. Strains with one estimated copy number have an activity of 42- 46 U/l and correlates well with the activity of two and three copy strains. We concluded that FINAL produces at least the same amount of proline specific endoprotease as WT1 under the same culture conditions.
Example 4
Comparison of phospholipase A1 (PLA1) production in WT1 and in FINAL strains We chose to express PLA1 from A. oryzae in WT 1 and in FINAL. The gene encoding this enzyme has already been published (Watanabe I, et al, Biosci. Biotechnol. Biochem. (1999), Vol 63, numero 5, pages 820-826). This gene was cloned into pGBFIN11 using the same technique as described in WO 02/045524 for the cloning of the proline specific endoprotease gene in pGBFIN11-EPO. This construct was introduced in these strains by cotransformation as described in WO 02/45524. Three independent transformants of WT1 and FINAL were tested for PLA1 expression in shakeflasks. The transformants with similar estimated copy number were cultivated in 100 ml of the same medium as described in EP 635 574 A1 at 34°C and 170 rpm in an incubator shaker using a 500 ml baffeled shake flask. After 2, 3, 4, 5 days of fermentation, samples were taken to determine the PLA1 activity. To determine phospholipase PLA1 activity from Aspergillus niger (PLA1 ) spectrophotometrically, an artificial substrate is used: 1 ,2-dithiodioctanoyl phophatidylcholine (diC8, substrate). PLA1 hydrolyses the sulphide bond at the A1 position, dissociating thio-octanoϊc acid. Thio-octanoϊc acid reacts with 4,4 dithiopyridine (color reagent, 4-DTDP), forming 4- thiopyridone. 4-Thiopyridone is in tautomeric equilibrium with 4-mercaptopyridine, which absorbs radiation having a wavelength of 334 nm. The extinction change at that wavelength is measured. One unit is the amount of enzyme that liberates of 1 nmol thio-octanoϊc acid from 1 ,2-dithiodioctanoyl phosphatidylcholine per minute at 37°C and pH 4.0. The substrate solution is prepared by dissolving 1 g diC8 crystals per 66 ml ethanol and add 264 ml acetate buffer. The acetate buffer comprises 0.1 M Acetate buffer pH 3.85 containing 0.2% Triton-X100. The colour reagent is a 11 mM 4,4-dithiodipyridine solution. It was prepared by weighting 5,0 mg 4,4-dithiodipyridine in a 2 ml eppendorf sample cup and dissolving in 1.00 ml ethanol. 1.00 ml of milli-Q water was added. The results are depicted in figure 14. It is shown that PLA1 activity in transformants of WT1 cultures decreased after 4-5 days. However, the PLA1 activity of transformants of FINAL accumulates during fermentation and no decrease in activity could be observed. We concluded that FINAL produces more PLA1 than the wild type counterpart it originates from under the same culture conditions.
INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule Ubis)
The indications made below relate to the microorganism referred to in the description on page 2 line 26 (and other pages)
IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet
Name of depositary institution
CENTRAAL BUREAU VOOR SCH1MMELCULTURES
Address of depositary institution (including postal code and country) Oosterstraat 1 P.O.Box 273 3740 AG BAARN The Netherlands
Date of deposit 10 August 1988 Accession Number CBS 513.:
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet
We inform you that the availability of the microorganism identified above, referred to Rule 13bis PCT, shall be effected only by issue of a sample to an expert nominated by the requester until the publication of the mention of grant of the national patent or, where applicable, for twenty years from the date of filing if the application has been refused, withdrawn or deemed to be withdrawn.
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")
Figure imgf000028_0001

Claims

1. An oxalate deficient A niger strain for the production of a given enzyme, wherein the oxalate deficient strain produces at least the same amount of the enzyme as the wild type strain it originates from under the same culture conditions.
2. An oxalate deficient A n/ger strain according to claim 1 , wherein the oxalate deficient strain produces more of the enzyme than the wild type strain it originates from under the same culture conditions.
3. An oxalate deficient strain according to claim 1 or 2, wherein the oxalate deficient strain has an intracellular OAH activity, which is between 1 % and 25% of the intracellular OAH activity of the wild type strain it originates from as detected in a model reaction.
4. An oxalate deficient A niger strain, characterized in that when the strain has been transformed with an expression construct comprising a gene coding for an enzyme, said strain produces at least the amount of the enzyme the wild type strain it originates from would produce under the same culture conditions, when the wild type strain has been transformed with the same expression construct as the oxalate deficient strain.
5. An oxalate deficient A niger strain according to claim 4, characterized in that the gene is an heterologous gene.
6. An oxalate deficient A niger strain according to any one of claims 1 to 5, wherein the strain produces at least the amount of enzyme the A. niger strain CBS 513.88 produced under the same culture condition, preferably more.
7. An oxalate deficient A. n/ger strain according to any one of claims 1 to 6, wherein the enzyme is a funga.l alpha amylase.
8. An oxalate deficient A niger strain according to claim 7, wherein the fungal alpha amylase is derived from Aspergillus oryzae or A. niger.
9. A method for obtaining oxalate deficient A niger strains which are suitable for producing at least the amount of enzyme the wild type strains they originate from produce under the same culture conditions, said method comprises the following steps: a) A niger is subjected to UV irradiation, b) MTP cultures of surviving colonies obtained in a) are realized under the culture conditions retained in a), c) a selection within the MTP cultures is performed in which mutants are selected that produce no more than half the amount of oxalate that the wild type strain they originate from produces under the same culture conditions, d) a second selection is performed within the mutants obtained in step c) in which mutants are selected that produce at least the amount of enzyme the wild type strains they originate from produce under the same culture conditions.
10. A method according to claim 9, wherein the method comprises an additional step e) wherein mutant selected in step d) are further selected to have an intracellular OAH activity, which is between 1 % and 25% of the intracellular OAH activity of the wild type strain it originates from as detected in a model reaction.
1 1. Use of an oxalate deficient A niger strain according to any one of claim 1 to 8 or obtainable by the process of any one of claims 9 or 10 for the production of a given enzyme.
PCT/EP2004/001173 2003-02-05 2004-02-05 Use of oxalate deficient aspergillus niger strains for producing a polypeptide WO2004070022A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/544,207 US20060127976A1 (en) 2003-02-05 2004-02-05 Use of oxalate deficient aspergillus niger strains for producing a polypeptide
AU2004209618A AU2004209618B2 (en) 2003-02-05 2004-02-05 Use of oxalate deficient aspergillus niger strains for producing a polypeptide
JP2006501780A JP2006516399A (en) 2003-02-05 2004-02-05 Use of an oxalate-deficient Aspergillus niger strain for the production of polypeptides
CA002513833A CA2513833A1 (en) 2003-02-05 2004-02-05 Use of oxalate deficient aspergillus niger strains for producing a polypeptide
EP04708360A EP1590444A2 (en) 2003-02-05 2004-02-05 Use of oxalate deficient aspergillus niger strains for producing a polypeptide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03100236 2003-02-05
EP03100236.3 2003-02-05

Publications (2)

Publication Number Publication Date
WO2004070022A2 true WO2004070022A2 (en) 2004-08-19
WO2004070022A3 WO2004070022A3 (en) 2004-10-28

Family

ID=32842807

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/001173 WO2004070022A2 (en) 2003-02-05 2004-02-05 Use of oxalate deficient aspergillus niger strains for producing a polypeptide

Country Status (7)

Country Link
US (1) US20060127976A1 (en)
EP (1) EP1590444A2 (en)
JP (1) JP2006516399A (en)
CN (1) CN1836033A (en)
AU (1) AU2004209618B2 (en)
CA (1) CA2513833A1 (en)
WO (1) WO2004070022A2 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010121933A1 (en) 2009-04-22 2010-10-28 Dsm Ip Assets B.V. Process for the production of a recombinant polypeptide of interest
WO2010122141A1 (en) 2009-04-24 2010-10-28 Dsm Ip Assets B.V. Carbohydrate degrading polypeptide and uses thereof
WO2011009700A1 (en) 2009-07-22 2011-01-27 Dsm Ip Assets B.V. Improved host cell for the production of a compound of interest
WO2011098577A1 (en) 2010-02-11 2011-08-18 Dsm Ip Assets B.V. Host cell capable of producing enzymes useful for degradation of lignocellulosic material
WO2011098580A1 (en) 2010-02-11 2011-08-18 Dsm Ip Assets B.V. Polypeptide having cellobiohydrolase activity and uses thereof
WO2012000891A1 (en) 2010-06-29 2012-01-05 Dsm Ip Assets B.V. Polypeptide having carbohydrate degrading activity and uses thereof
WO2012000887A1 (en) 2010-06-29 2012-01-05 Dsm Ip Assets B.V. Polypeptide having swollenin activity and uses thereof
WO2012000892A1 (en) 2010-06-29 2012-01-05 Dsm Ip Assets B.V. Polypeptide having or assisting in carbohydrate material degrading activity and uses thereof
WO2012000890A1 (en) 2010-06-29 2012-01-05 Dsm Ip Assets B.V. Polypeptide having beta-glucosidase activity and uses thereof
WO2012000888A1 (en) 2010-06-29 2012-01-05 Dsm Ip Assets B.V. Polypeptide having acetyl xylan esterase activity and uses thereof
WO2012000886A1 (en) 2010-06-29 2012-01-05 Dsm Ip Assets B.V. Polypeptide having beta-glucosidase activity and uses thereof
EP2410048A1 (en) 2005-01-24 2012-01-25 DSM IP Assets B.V. Method for producing a compound of interest in a filamentous fungal cell
EP2423315A1 (en) 2006-06-29 2012-02-29 DSM IP Assets B.V. A method for achieving improved polypeptide expression
EP2458008A1 (en) 2005-11-29 2012-05-30 DSM IP Assets B.V. DNA binding site of a transcriptional activator useful in gene expression
WO2012123429A1 (en) 2011-03-11 2012-09-20 Dsm Ip Assets B.V. Vector-host system
EP2511372A1 (en) 2006-11-02 2012-10-17 DSM IP Assets B.V. Improved production of secreted proteins by filamentous fungi
EP2631295A2 (en) 2007-02-15 2013-08-28 DSM IP Assets B.V. A recombinant host cell for the production of a compound of interest
WO2014013074A1 (en) 2012-07-19 2014-01-23 Dsm Ip Assets B.V. Agse-deficient strain
WO2014044782A1 (en) 2012-09-19 2014-03-27 Dsm Ip Assets B.V. Cell modification method using essential genes as markers and optionally recycling these
WO2015082488A1 (en) 2013-12-02 2015-06-11 Dsm Ip Assets B.V. Ice structuring protein
WO2016110453A1 (en) 2015-01-06 2016-07-14 Dsm Ip Assets B.V. A crispr-cas system for a filamentous fungal host cell
WO2016193292A1 (en) 2015-06-02 2016-12-08 Dsm Ip Assets B.V. Use of ice structuring protein afp19 expressed in filamentous fungal strains for preparing food
WO2018166943A1 (en) 2017-03-13 2018-09-20 Dsm Ip Assets B.V. Zinc binuclear cluster transcriptional regulator-deficient strain
WO2019215078A1 (en) 2018-05-07 2019-11-14 Dsm Ip Assets B.V. Process for enzymatic oil degumming

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007063133A2 (en) 2005-12-01 2007-06-07 Dsm Ip Assets B.V. Genes useful for the industrial production of citric acid
CN108368153B (en) * 2015-08-10 2022-11-15 帕拉贝尔营养股份有限公司 Method and system for extracting reduced oxalate protein from aquatic species and compositions thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518697A (en) * 1981-12-14 1985-05-21 Henkel Kommanditgesellschaft Auf Aktien Acid stable protease from mutants of genus Aspergillus
WO1997010350A1 (en) * 1995-09-11 1997-03-20 Likospol S.R.O. Process, apparatus and microorganism strain for the manufacture of citric acid
WO2000050576A1 (en) * 1999-02-22 2000-08-31 Novozymes A/S Oxaloacetate hydrolase deficient fungal host cells
US6432672B1 (en) * 1997-04-11 2002-08-13 Gerardus Cornelis Maria Selten Gene conversion as a tool for the construction of recombinant industrial filamentous fungi

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518697A (en) * 1981-12-14 1985-05-21 Henkel Kommanditgesellschaft Auf Aktien Acid stable protease from mutants of genus Aspergillus
WO1997010350A1 (en) * 1995-09-11 1997-03-20 Likospol S.R.O. Process, apparatus and microorganism strain for the manufacture of citric acid
US6432672B1 (en) * 1997-04-11 2002-08-13 Gerardus Cornelis Maria Selten Gene conversion as a tool for the construction of recombinant industrial filamentous fungi
WO2000050576A1 (en) * 1999-02-22 2000-08-31 Novozymes A/S Oxaloacetate hydrolase deficient fungal host cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HOMBERGH VAN DEN J P T W ET AL: "NEW PROTEASE MUTANTS IN ASPERGILLUS NIGER RESULTS IN STRONGLY REDUCED IN VITRO DEGRADATION OF TARGET PROTEINS;GENETICAL AND BIOCHEMICAL CHARACTERIZATION OF SEVEN COMPLEMENTATION GROUPS" CURRENT GENETICS, NEW YORK, NY, US, vol. 28, no. 4, 1995, pages 299-308, XP000867320 ISSN: 0172-8083 *
PEDERSEN H ET AL: "Construction and characterization of an oxalic acid nonproducing strain of Aspergillus niger." METABOLIC ENGINEERING. UNITED STATES JAN 2000, vol. 2, no. 1, January 2000 (2000-01), pages 34-41, XP002286173 ISSN: 1096-7176 cited in the application *
RUIJTER G J G ET AL: "OXALIC ACID PRODUCTION BY ASPERGILLUS NIGER: AN OXALATE-NON-PRODUCING MUTANT PRODUCES CITRIC ACID AT PH 5 AND IN THE PRESENCE OF MANGANESE" MICROBIOLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, READING, GB, vol. 145, no. 9, September 1999 (1999-09), pages 2569-2576, XP000905457 ISSN: 1350-0872 *
SARANGBIN S ET AL: "Yam bean starch: a novel substrate for citric acid production by the protease-negative mutant strain of Aspergillus niger" CARBOHYDRATE POLYMERS, APPLIED SCIENCE PUBLISHERS, LTD. BARKING, GB, vol. 38, no. 3, March 1999 (1999-03), pages 219-224, XP004154847 ISSN: 0144-8617 *

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2410048A1 (en) 2005-01-24 2012-01-25 DSM IP Assets B.V. Method for producing a compound of interest in a filamentous fungal cell
EP2458007A1 (en) 2005-11-29 2012-05-30 DSM IP Assets B.V. DNA binding site of a transcriptional activator useful in gene expression
EP2458008A1 (en) 2005-11-29 2012-05-30 DSM IP Assets B.V. DNA binding site of a transcriptional activator useful in gene expression
EP2423315A1 (en) 2006-06-29 2012-02-29 DSM IP Assets B.V. A method for achieving improved polypeptide expression
EP2511372A1 (en) 2006-11-02 2012-10-17 DSM IP Assets B.V. Improved production of secreted proteins by filamentous fungi
EP2631295A2 (en) 2007-02-15 2013-08-28 DSM IP Assets B.V. A recombinant host cell for the production of a compound of interest
WO2010121933A1 (en) 2009-04-22 2010-10-28 Dsm Ip Assets B.V. Process for the production of a recombinant polypeptide of interest
WO2010122141A1 (en) 2009-04-24 2010-10-28 Dsm Ip Assets B.V. Carbohydrate degrading polypeptide and uses thereof
EP3293264A1 (en) 2009-07-22 2018-03-14 DSM IP Assets B.V. Improved host cell for the production of a compound of interest
WO2011009700A1 (en) 2009-07-22 2011-01-27 Dsm Ip Assets B.V. Improved host cell for the production of a compound of interest
US11753631B2 (en) 2010-02-11 2023-09-12 Versalis S.P.A. Host cell capable of producing enzymes useful for degradation of lignocellulosic material
US10035999B2 (en) 2010-02-11 2018-07-31 Dsm Ip Assets B.V. Host cell capable of producing enzymes useful for degradation of lignocellulosic material
US10077435B2 (en) 2010-02-11 2018-09-18 Dsm Ip Assets B.V. Host cell capable of producing enzymes useful for degradation of lignocellulosic material
US10920207B2 (en) 2010-02-11 2021-02-16 Dsm Ip Assets B.V. Host cell capable of producing enzymes useful for degradation of lignocellulosic material
AU2011214324B2 (en) * 2010-02-11 2014-11-20 Dsm Ip Assets B.V. Host cell capable of producing enzymes useful for degradation of lignocellulosic material
US9738881B2 (en) 2010-02-11 2017-08-22 Dsm Ip Assets B.V. Host cell capable of producing enzymes useful for degradation of lignocellulosic material
WO2011098580A1 (en) 2010-02-11 2011-08-18 Dsm Ip Assets B.V. Polypeptide having cellobiohydrolase activity and uses thereof
CN102762727A (en) * 2010-02-11 2012-10-31 帝斯曼知识产权资产管理有限公司 Host cell capable of producing enzymes useful for degradation of lignocellulosic material
WO2011098577A1 (en) 2010-02-11 2011-08-18 Dsm Ip Assets B.V. Host cell capable of producing enzymes useful for degradation of lignocellulosic material
CN102762727B (en) * 2010-02-11 2016-07-20 帝斯曼知识产权资产管理有限公司 The host cell of the enzyme for lignocellulose degradation material can be produced
US9109214B2 (en) 2010-02-11 2015-08-18 Dsm Ip Assets B.V. Host cell capable of producing enzymes useful for degradation of lignocellulosic material
WO2012000890A1 (en) 2010-06-29 2012-01-05 Dsm Ip Assets B.V. Polypeptide having beta-glucosidase activity and uses thereof
WO2012000886A1 (en) 2010-06-29 2012-01-05 Dsm Ip Assets B.V. Polypeptide having beta-glucosidase activity and uses thereof
WO2012000891A1 (en) 2010-06-29 2012-01-05 Dsm Ip Assets B.V. Polypeptide having carbohydrate degrading activity and uses thereof
WO2012000887A1 (en) 2010-06-29 2012-01-05 Dsm Ip Assets B.V. Polypeptide having swollenin activity and uses thereof
WO2012000892A1 (en) 2010-06-29 2012-01-05 Dsm Ip Assets B.V. Polypeptide having or assisting in carbohydrate material degrading activity and uses thereof
WO2012000888A1 (en) 2010-06-29 2012-01-05 Dsm Ip Assets B.V. Polypeptide having acetyl xylan esterase activity and uses thereof
WO2012123429A1 (en) 2011-03-11 2012-09-20 Dsm Ip Assets B.V. Vector-host system
WO2014013074A1 (en) 2012-07-19 2014-01-23 Dsm Ip Assets B.V. Agse-deficient strain
WO2014044782A1 (en) 2012-09-19 2014-03-27 Dsm Ip Assets B.V. Cell modification method using essential genes as markers and optionally recycling these
WO2015082488A1 (en) 2013-12-02 2015-06-11 Dsm Ip Assets B.V. Ice structuring protein
WO2016110453A1 (en) 2015-01-06 2016-07-14 Dsm Ip Assets B.V. A crispr-cas system for a filamentous fungal host cell
WO2016193292A1 (en) 2015-06-02 2016-12-08 Dsm Ip Assets B.V. Use of ice structuring protein afp19 expressed in filamentous fungal strains for preparing food
WO2018166943A1 (en) 2017-03-13 2018-09-20 Dsm Ip Assets B.V. Zinc binuclear cluster transcriptional regulator-deficient strain
WO2019215078A1 (en) 2018-05-07 2019-11-14 Dsm Ip Assets B.V. Process for enzymatic oil degumming

Also Published As

Publication number Publication date
AU2004209618B2 (en) 2008-04-17
CN1836033A (en) 2006-09-20
US20060127976A1 (en) 2006-06-15
AU2004209618A1 (en) 2004-08-19
EP1590444A2 (en) 2005-11-02
CA2513833A1 (en) 2004-08-19
JP2006516399A (en) 2006-07-06
WO2004070022A3 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
AU2004209618B2 (en) Use of oxalate deficient aspergillus niger strains for producing a polypeptide
US9322045B2 (en) Host cell for the production of a compound of interest
CN105308171B (en) AGSE defect bacterial strain
EP1266011B1 (en) Fungal transcriptional activator useful in methods for producing polypeptides
MX2011009059A (en) Method for improving the yield of a polypeptide.
US20100112638A1 (en) Recombinant host cell for the production of a compound of interest
CA2803222A1 (en) A method for the production of a compound of interest
AU2005254734A1 (en) Production of polypeptides by improved secretion
JP2002539793A (en) Promoters for expressing genes in fungal cells
JP2018504936A (en) Fungal strains and methods of use
JP4563585B2 (en) Fungal transcriptional activators useful in polypeptide production methods
JP2019503168A (en) Method for producing a protein in a filamentous fungus with reduced CLR2 activity
US20130189733A1 (en) Production of secreted proteins by filamentous fungi
US8298787B2 (en) Methods for enhancing a secretion efficiency of recombinant foreign protein in yeast expression system
JP2019501646A (en) Method for producing a protein in a filamentous fungus with reduced CLR1 activity
JP4756125B2 (en) Novel mutants and selectable markers of Aspergillus oryzae
EP2531590A2 (en) Process for preparing filamentous fungal strains having a sexual cycle and a process for preparing sexually crossed filamentous fungal strains
US20220267783A1 (en) Filamentous fungal expression system
KR20020059350A (en) Use of aspergillus sojae as host for recombinant protein producion

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2004209618

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2513833

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004708360

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006501780

Country of ref document: JP

Ref document number: 20048036436

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004209618

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2006127976

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10544207

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2004708360

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10544207

Country of ref document: US